Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022.

“Despite macro pressures and the poor optics of our financial results, Stereotaxis is making significant progress commercially and technologically,” said David Fischel, Chairman and CEO. “I am pleased with our progress and confident in where we stand and the path ahead of us. We see continued demand for our technology, are advancing a transformative innovation pipeline, and are assembling an all-star commercial team, all while maintaining financial stability and strength.”

“We received three orders for Genesis systems during the second quarter, two since our last call and one of which will become a second active robot at a prestigious US hospital. The recent CE Mark submission for the MAGiC ablation catheter is reflective of the methodical progress being made across multiple fronts on our strategic innovation plan. We continue to anticipate multiple highly impactful technologies to be launched throughout 2023 and beyond. As these launches approach we are placing increased focus on ensuring the right commercial team, infrastructure and processes are in place to drive substantial revenue growth. The addition of highly experienced commercial leaders to our team is a testament to the opportunity in front of us.”

2022 Second Quarter Financial ResultsRevenue for the second quarter of 2022 totaled $6.2 million, compared to $9.1 million in the prior year second quarter with the decrease primarily driven by lower revenue recognition of system sales in the current quarter. System revenue for the second quarter was $0.6 million and recurring revenue was $5.6 million.

Gross margin for the second quarter of 2022 was 76% of revenue, with system gross margin of 16% and recurring revenue gross margin of 83%. Operating expenses in the quarter of $9.8 million include $2.7 million in non-cash stock compensation expense. Excluding stock compensation expense, adjusted operating expenses were $7.2 million, consistent with the prior year second quarter.

Operating loss and net loss for the second quarter of 2022 were both approximately ($5.2) million, compared to a ($3.4) million operating loss and a ($1.2) million net loss in the previous year. Net loss in the prior year quarter reflects a favorable $2.2 million adjustment for the forgiveness of the Paycheck Protection Loan. Adjusted operating loss and adjusted net loss for the quarter, excluding non-cash stock compensation expense, were both ($2.5) million. Negative free cash flow for the second quarter was ($1.8) million.

Cash Balance and LiquidityAt June 30, 2022, Stereotaxis had cash and cash equivalents, including restricted cash, of $35.1 million and no debt.

Forward Looking ExpectationsRevenue for the first half of this year represents a nadir in performance with results in the second half expected to be substantially higher. Stereotaxis’ current system backlog of over $12 million supports its prior guidance of overall revenue growth in 2022. While this guidance remains achievable, significant variability in hospital construction timelines suggests that a sufficient portion of backlog may be recognized as revenue in the following year, introducing caution to this guidance. Substantial and consistent revenue growth in the coming years is expected to be supported by new technology launches and an enhanced commercial organization. Stereotaxis expects to end the year with approximately $32 million in cash and cash equivalents, maintaining a robust balance sheet that allows it to reach profitability without the need for additional financings.

Conference Call and WebcastStereotaxis will host a conference call and webcast today, August 9, 2022, at 10:00 a.m. Eastern Time. To access the conference call, dial 1-888-394-8218 (US and Canada) or 1-856-344-9221 (International) and give the participant pass code 9211068. Participants are asked to call 5-10 minutes prior to the start time. To access the live and replay webcast, please visit the investor relations section of the Stereotaxis website at

About StereotaxisStereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.

Investor Contacts:     Media Contact:
David L. Fischel       Bethanne Schluter
Chairman and Chief Executive Officer      Director, Marketing & Communications
Kimberly Peery      
Chief Financial Officer      

(in thousands, except share and per share amounts) Three Months EndedJune 30,   Six Months EndedJune 30,
  2022   2021   2022   2021
Systems $ 602     $ 2,686     $ 2,236     $ 5,289  
Disposables, service and accessories   5,550       6,118       10,953       11,892  
Sublease   -       247       -       493  
Total revenue   6,152       9,051       13,189       17,674  
Cost of revenue:              
Systems   509       1,390       1,801       2,825  
Disposables, service and accessories   973       882       1,794       1,808  
Sublease   -       247       -       493  
Total cost of revenue   1,482       2,519       3,595       5,126  
Gross margin   4,670       6,532       9,594       12,548  
Operating expenses:              
Research and development   2,893       2,717       5,340       5,084  
Sales and marketing   3,279       3,045       6,225       5,992  
General and administrative   3,677       4,161       7,297       6,391  
Total operating expenses   9,849       9,923       18,862       17,467  
Operating loss   (5,179 )     (3,391 )     (9,268 )     (4,919 )
Interest (expense) income, net   45       (3 )     48       (7 )
Gain on extinguishment of debt   -       2,183       -       2,183  
Net loss $ (5,134 )   $ (1,211 )   $ (9,220 )   $ (2,743 )
Cumulative dividend on convertible preferred stock   (335 )     (335 )     (666 )     (668 )
Net loss attributable to common stockholders $ (5,469 )   $ (1,546 )   $ (9,886 )   $ (3,411 )
Net loss per share attributed to common stockholders:              
Basic $ (0.07 )   $ (0.02 )   $ (0.13 )   $ (0.05 )
Diluted $ (0.07 )   $ (0.02 )   $ (0.13 )   $ (0.05 )
Weighted average number of common shares and equivalents:              
Basic   75,953,916       75,547,574       75,915,864       75,362,521  
Diluted   75,953,916       75,547,574       75,915,864       75,362,521  


(in thousands, except share amounts) June 30, 2022   December 31, 2021
Current assets:      
Cash and cash equivalents $ 33,498     $ 38,739  
Restricted cash - current   618       454  
Accounts receivable, net of allowance of $225 and $180 at 2022 and 2021, respectively   3,748       5,406  
Inventories, net   7,786       4,433  
Prepaid expenses and other current assets   991       2,356  
Total current assets   46,641       51,388  
Property and equipment, net   3,260       2,632  
Restricted cash   1,006       952  
Operating lease right-of-use assets   5,553       5,735  
Prepaid and other non-current assets   218       278  
Total assets $ 56,678     $ 60,985  
Liabilities and stockholders' equity      
Current liabilities:      
Accounts payable $ 4,244     $ 4,189  
Accrued liabilities   2,126       2,528  
Deferred revenue   6,959       6,277  
Current portion of operating lease liabilities   328       268  
Total current liabilities   13,657       13,262  
Long-term deferred revenue   1,630       2,238  
Operating lease liabilities   5,663       5,842  
Other liabilities   202       219  
Total liabilities   21,152       21,561  
Series A - Convertible preferred stock:      
Convertible preferred stock, Series A, par value $0.001; 22,386 and 22,387 shares outstanding at 2022 and 2021, respectively   5,584       5,584  
Stockholders' equity:      
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2022 and 2021   6       6  
Common stock, par value $0.001; 300,000,000 shares authorized, 74,686,056 and 74,618,240 shares issued at 2022 and 2021, respectively   75       75  
Additional paid-in capital   537,963       532,641  
Treasury stock, 4,015 shares at 2022 and 2021   (206 )     (206 )
Accumulated deficit   (507,896 )     (498,676 )
Total stockholders' equity   29,942       33,840  
Total liabilities and stockholders' equity $ 56,678     $ 60,985  
Stereotaxis (AMEX:STXS)
Graphique Historique de l'Action
De Nov 2023 à Déc 2023 Plus de graphiques de la Bourse Stereotaxis
Stereotaxis (AMEX:STXS)
Graphique Historique de l'Action
De Déc 2022 à Déc 2023 Plus de graphiques de la Bourse Stereotaxis